## FORM 4

## **UNITED STATES SECU**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

or Section 30(h) of the Investment Company Act of 1940

Washington, D.C. 20549

RITIES AND EXCHANGE COMMIS	SION
----------------------------	------

**OMB APPROVAL** OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

See

footnote(7)

T

1,541,667

Check this box if no longer subject to

Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

1. Name and Address of Reporting Person* <u>JEFFS ROGER</u>				2. Issuer Name <b>and</b> Ticker or Trading Symbol Liquidia Corp [ LQDA ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)    Director 10% Owner				
(Last) 419 DAVIS DRIV	(First) VE, SUITE 100	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/11/2025							Officer (give title Other (specify below)  Chief Executive Officer				
(Street) MORRISVILLE (City)	NC (State)	27560 (Zip)								6. Indi Line)	<u>,</u>				
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned															
Date		2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
						Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		
Common Stock			01/11/2	2025		<b>A</b> <sup>(1)</sup>		229,327(2)	A	\$0	1,041,520(3)	D			
Common Stock			01/14/2	2025		S <sup>(4)</sup>		22,343(5)	D	\$11.78	1,019,177(3)	D			
Common Stock											46,595	I	See footnote(6)		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)	Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Performance Stock Units	(8)	01/11/2025		A		229,327		(9)	(9)	Common Stock	229,327	\$0	229,327	D	

## **Explanation of Responses:**

Common Stock

- 1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- 2. 25% of the RSUs shall vest on January 11, 2026 and the remaining RSUs shall vest ratably on a quarterly basis over three years thereafter.
- 2024 and (iii) 8,483 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.
- 4. Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023.
- 5. These shares of common stock were sold to cover taxes associated with the settlement of RSUs that were initially granted to the Reporting Person on January 11, 2023 and January 11, 2024.
- 6. The securities are held by Roger A. Jeffs Living Trust UAD 2/29/2000 (the "Trust"). The Reporting Person is the trustee of the Trust.
- 7. The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by
- 8. Each performance stock unit ("PSU") converts into one share of the Issuer's common stock.
- 9. On January 11, 2025, the Reporting Person was granted 229,327 PSUs. The PSUs shall vest upon the later of (A) the following time-based vesting schedule: 25% of the PSUs shall vest on January 11, 2026 and the remaining PSUs shall vest ratably on a quarterly basis over three years thereafter, and (B) the first commercial sale of YUTREPIA by the Issuer.

01/14/2025 /s/ Roger Jeffs \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.